InVision Precision Cardiac Amyloid vs syngo.CT CaScoring

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

InVision Precision Cardiac Amyloid

by InVision Medical Technology

syngo.CT CaScoring

by Siemens Healthineers

AI Verdict

Tool A is designed for the early detection of cardiac amyloidosis using echocardiography, focusing on a specific, often underdiagnosed disease. In contrast, Tool B quantifies coronary artery calcifications from CT scans to assess cardiovascular risk and plaque burden. Therefore, clinicians would choose Tool A for diagnosing cardiac amyloidosis and Tool B for evaluating coronary artery disease risk.

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your primary objective is the early and accurate detection of cardiac amyloidosis in patients presenting with heart failure symptoms. This AI-powered software leverages echocardiography to identify both AL and ATTR types, aiming to reduce misdiagnosis and improve patient outcomes through precise assessment of wall thickness.

View InVision Precision Cardiac Amyloid →

Choose syngo.CT CaScoring if…

Choose syngo.CT CaScoring if you need to precisely quantify and visualize calcified coronary lesions from CT scans for comprehensive cardiovascular risk assessment. This tool provides critical metrics like the Agatston Score and 'Coronary Age', enabling clinicians to assess plaque burden and compare patient scores to healthy reference groups for effective risk stratification.

View syngo.CT CaScoring →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	InVision Precision Cardiac Amyloid	syngo.CT CaScoring
Pricing	Unknown	Contact for pricing
Deployment	Cloud or on-premise	Integrated with Siemens CT scanner systems; operates as a post-processing application on the multi-user syngo.via client/server platform.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools are designed for integration into existing clinical workflows within their respective modalities. Tool A integrates into echocardiography labs, while Tool B integrates into the Siemens CT and syngo.via ecosystem, both aiming for efficiency and ease of use for their target users.

Clinical Value

InVision Precision Cardiac Amyloid

Tool A focuses on the earlier detection and reduction of misdiagnosis for cardiac amyloidosis, a life-threatening and often underdiagnosed disease, backed by a peer-reviewed publication in JAMA Cardiology. This addresses a critical unmet need with potentially transformative patient outcomes. Tool B, while valuable, primarily automates and refines an existing cardiovascular risk assessment method.

Pricing & Value

InVision Precision Cardiac Amyloid

Tool A offers transparent, subscription-based pricing starting at a clear monthly cost, providing an accessible entry point for users. Tool B's pricing is less transparent, requiring contact for details on a one-time license purchase, and its historical pricing information is outdated.

Enterprise Readiness

syngo.CT CaScoring

Tool B, developed by Siemens Medical Solutions USA, benefits from being part of a global leader in medical technology with an established enterprise footprint, robust support infrastructure, and deep integration capabilities within large healthcare systems via its syngo.via platform. While Tool A is FDA cleared and HIPAA compliant, Siemens' scale and existing relationships with enterprise clients give Tool B a significant advantage in enterprise readiness.

Innovation

InVision Precision Cardiac Amyloid

Tool A's application of AI to detect cardiac amyloidosis from echocardiograms, addressing a complex, often missed, and life-threatening condition, represents a more significant innovative leap in diagnostic capability. Tool B applies AI to automate and refine an already established risk scoring method for coronary calcifications.

Support & Docs

syngo.CT CaScoring

As a product from Siemens Medical Solutions USA, a leading global healthcare technology provider, Tool B benefits from Siemens' extensive global support infrastructure, comprehensive documentation, and established training programs, which are typically robust for enterprise-level solutions. InVision Medical Technology Corporation, while likely offering support, is a smaller entity and unlikely to match the scale and breadth of Siemens' support ecosystem.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	InVision Precision Cardiac Amyloid	syngo.CT CaScoring
Name	InVision Precision Cardiac Amyloid	syngo.CT CaScoring
Company	InVision Medical Technology Corporation	Siemens Medical Solutions USA
Primary Clinical Focus	Detection of cardiac amyloidosis	Quantification and visualization of calcified coronary lesions for cardiovascular risk assessment
Input Imaging Modality	Echocardiography (transthoracic echocardiogram studies)	CT scans
Key AI Functionality	AI-powered detection of cardiac amyloidosis; precise assessment of wall thickness	AI-powered quantification and accurate visualization of calcified coronary lesions; automatic highlighting of coronary calcifications
Specific Output Metrics/Scores	Not specified	Agatston Score, volume, calcium mass, plaque burden (total and per coronary artery), 'Coronary Age'

Videos

Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and syngo.CT CaScoring.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiac conditions do these tools help diagnose or assess?

InVision Precision Cardiac Amyloid is designed for the AI-powered detection of cardiac amyloidosis, supporting both AL and ATTR types. syngo.CT CaScoring focuses on the quantification and visualization of calcified coronary lesions to aid in cardiovascular risk assessment.

Which imaging modalities are required for each tool?

InVision Precision Cardiac Amyloid evaluates transthoracic echocardiogram studies, specifically apical-4-chamber and parasternal-long-axis view videos. syngo.CT CaScoring analyzes CT scans to quantify and visualize coronary calcifications.

What are the key quantitative metrics or scores provided by each tool?

InVision Precision Cardiac Amyloid offers AI-powered detection of cardiac amyloidosis and precise assessment of wall thickness. syngo.CT CaScoring calculates the Agatston Score, volume, and calcium mass, and provides an assessment of plaque burden and 'Coronary Age'.

How do these tools integrate into existing clinical workflows?

InVision Precision Cardiac Amyloid is deployed as Software as a Medical Device (SaMD) and integrates into clinical workflows for echocardiography labs. syngo.CT CaScoring is integrated with Siemens CT scanner systems and operates as a post-processing application on the multi-user syngo.via client/server platform.

What evidence supports the clinical utility of these tools?

InVision Precision Cardiac Amyloid's AI algorithm is evidence-based, peer-reviewed, and published in JAMA Cardiology. syngo.CT CaScoring supports the comparison of a patient's score to healthy reference groups, such as the MESA study, for cardiovascular risk assessment.